GUD Stock Overview
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for GUD from our risk checks.
Knight Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$5.79 |
| 52 Week High | CA$5.95 |
| 52 Week Low | CA$4.35 |
| Beta | 0.48 |
| 1 Month Change | 7.22% |
| 3 Month Change | 1.22% |
| 1 Year Change | 20.37% |
| 3 Year Change | 10.50% |
| 5 Year Change | -20.79% |
| Change since IPO | 51.17% |
Recent News & Updates
Recent updates
Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?
May 28
Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why
May 07Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)
Apr 07Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares
Mar 20If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%
Mar 02Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 03
Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?
Jan 19What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?
Jan 04A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)
Dec 20The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares
Dec 07What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Dec 02Need To Know: The Consensus Just Cut Its Knight Therapeutics Inc. (TSE:GUD) Estimates For 2021
Nov 17Shareholder Returns
| GUD | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -1.4% | -4.9% | -1.9% |
| 1Y | 20.4% | 55.7% | 3.7% |
Return vs Industry: GUD underperformed the Canadian Pharmaceuticals industry which returned 58% over the past year.
Return vs Market: GUD exceeded the Canadian Market which returned 3.6% over the past year.
Price Volatility
| GUD volatility | |
|---|---|
| GUD Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 14.1% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: GUD has not had significant price volatility in the past 3 months.
Volatility Over Time: GUD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 725 | Samira Sakhia | www.gud-knight.com |
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation.
Knight Therapeutics Inc. Fundamentals Summary
| GUD fundamental statistics | |
|---|---|
| Market cap | CA$585.78m |
| Earnings (TTM) | -CA$16.83m |
| Revenue (TTM) | CA$328.20m |
1.8x
P/S Ratio-34.8x
P/E RatioIs GUD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GUD income statement (TTM) | |
|---|---|
| Revenue | CA$328.20m |
| Cost of Revenue | CA$175.55m |
| Gross Profit | CA$152.65m |
| Other Expenses | CA$169.49m |
| Earnings | -CA$16.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 46.51% |
| Net Profit Margin | -5.13% |
| Debt/Equity Ratio | 8.3% |
How did GUD perform over the long term?
See historical performance and comparison